Home > Newsletters > Washington Drug Letter > Forest Gets Untitled Letter After Reps Downplay Weight-Loss Risks
Washington Drug Letter
Aug. 13, 2012 | Vol. 44 No. 32
Forest Gets Untitled Letter After Reps Downplay Weight-Loss Risks
Forest Laboratories has been hit with an untitled letter after two of its sales reps implied that weight loss while using Daliresp tablets — listed as an adverse reaction — could be beneficial for overweight chronic obstructive pulmonary disease (COPD) patients.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.